Copyright
©The Author(s) 2022.
World J Clin Cases. Dec 26, 2022; 10(36): 13216-13226
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13216
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13216
Table 1 Literature survey papers
| Ref. | Publication date | Journal | Sample size | Subjects | Limitations |
| Park et al[22] | January 4, 2022 | Clinical Infection Disease | 108 | Delta Variant | Statistic of fully vaccinated sample not included, sample from different ethnic |
| Hu et al[23] | March 1, 2022 | Frontiers in Medicine | 156 | Delta Variant Fully Vaccinated | Sample from different ethnic |
Table 2 Demographic statistics of the subjects enrolled
| Demographic factor | All | |
| Subjects, n | 15 | |
| Age class, n (%) | ||
| 21-25 | 3 (20) | |
| 26-30 | 5 (33.34) | |
| 31-35 | 4 (26.67) | |
| 35-40 | 3 (20) | |
| Age in yr, mean ± SD | 29.87 ± 5.097 | |
| Sex | ||
| Male | 10 (66.67) | |
| Female | 5 (33.33) | |
| Height in cm, mean ± SD | 167.00 ± 8.384 | |
| Weight in kg, mean ± SD | 69.20 ± 11.706 | |
| Body mass index as kg/m2, mean ± SD | 24.768 ± 3.531 | |
| Occupation, n (%) | ||
| Employee | 11 (73.34) | |
| Medical students | 1 (6.67) | |
| Residents | 3 (20) | |
| Comorbidity, n (%) | 2 (13.34) | |
| Chronic respiratory disease | 1 (6.67) | |
| Obesity | 1 (6.67) | |
| Vaccination type, n (%) | ||
| CoronaVac (Sinovac) | 14 (93.34) | |
| ChAdOx1 nCoV-19 (Oxford-AstraZeneca) | 1 (6.67) | |
Table 3 Clinical characteristics of the subjects enrolled
| Characteristic | All | |
| Reinfection, n (%) | 1 (6.67) | |
| Predicted source of infection, n (%) | ||
| Family | 3 (20) | |
| Patient | 3 (20) | |
| Coworker | 7 (46.67) | |
| Unknown | 2 (13.34) | |
| Mask usage during outside activity, n (%) | ||
| Surgical mask | 11 (73.34) | |
| N95 mask | 3 (20) | |
| KN95 mask | 1 (6.67) | |
| Symptoms, n (%) | ||
| Fever | 10 (66.67) | |
| Cough | 7 (46.67) | |
| Rhinorrhea | 9 (60) | |
| Headache | 5 (33.34) | |
| Sore throat | 2 (13.34) | |
| Anosmia | 8 (53.34) | |
| Ageusia/Dysgeusia | 4 (26.67) | |
| Diarrhea | 3 (20) | |
| Fatigue | 4 (26.67) | |
| Myalgia | 4 (26.67) | |
| Dyspnea | 1 (6.67) | |
| Nausea | 1 (6.67) | |
| Time in d of symptom duration, mean ± SD | 7.73 ± 5.444 | |
| Time in d of PCR conversion, mean ± SD | 17.93 ± 6.364 | |
| Time in d that elapsed from second dose of vaccine to a positive PCR result, median IQR | 87 (86-128.00) | |
| In-home isolation, n (%) | 15 (100) | |
| Drug treatment, n (%) | ||
| Vitamin C | 14 (93.34) | |
| Vitamin D | 12 (80) | |
| Paracetamol | 8 (53.34) | |
| Azithromycin | 5 (33.34) | |
| Oseltamivir | 1 (6.67) | |
| Favipiravir | 3 (20) | |
| Phytopharmaca | 1 (6.67) | |
Table 4 Comparative study with other paper
| Our study (n = 15) | Park et al[22] (n = 108) | Hu et al[23] (n = 156) | |
| Age | 29.87 ± 5.097 | 34.5 (26.5-46.0) | 43.0 (33.0-56.8) |
| Comorbidity | |||
| Hypertension | 12 (11.1) | 31 (19.9) | |
| Hyperlipidaemia | 4 (3.7) | ||
| Diabetes | 7 (6.5) | 9 (5.8) | |
| Psychiatric illness | 1(0.9) | ||
| Cancer | 1 (0.9) | ||
| Obesity (BMI > 30) | 1 (6.67) | 12 (11.1) | |
| Cardiovascular disease | 5 (3.2) | ||
| Respiratory disease | 1 (6.67) | ||
| Symptoms | |||
| Fever | 10 (66.67) | 73 (73.7) | 54 (34.6) |
| Cough | 7 (46.67) | 49 (49.5) | 76 (48.7) |
| Rhinorrhoea | 9 (60) | 4 (4.0) | |
| Headache | 5 (33.34) | 34 (34.3) | |
| Sore throat | 2 (13.34) | 43 (43.4) | 40 (25.6) |
| Anosmia | 8 (53.34) | 7 (7.1) | |
| Ageusia/dysgeusia | 4 (26.67) | 2 (2.0) | |
| Diarrhoea | 3 (20) | 3 (3.0) | 14 (9.0) |
| Fatigue | 4 (26.67) | 30 (19.2) | |
| Myalgia | 4 (26.67) | ||
| Dyspnoea | 1 (6.67) | 1 (1.0) | 1 (0.6) |
| Nausea | 1 (6.67) |
Table 5 Research gap analysis
| Ref. | Reasons(s) for gap | Population | Results | Free text of gap |
| Park et al[22] | D | Delta variant | A total of 141 patients [Delta group, n = 108 (77%); non-Delta group, n = 33 (23%)]; Delta group: Median age 34.5 (26.5-46.0); Hypertension 12 (11.1); Hyperlidemia 2 (6.1); Diabetes 5 (15.2); Psychiatric Illness 1(3.0); Asthma/Rhinitis 1 (3.0); Cancer 1 (3.0); Obesity BMI > 30.4 (12.1) | Results may not be applicable for reference as full vaccinated criteria not included and our subject only had chronic respiratory disease 1 (6.67) and obesity 1 (6.67) |
| Hu et al[23] | D | Delta variant fully vaccinated | A total of 677 patients (Wild type = 341; Delta unvaccinated = 120; Delta Partially vaccinated = 60; Delta fully vaccinated = 156); Delta fully vaccinated: Median age 43.0 (33.0-56.8); Hypertension 31 (19.9); Diabetes 9 (5.8); Cardiovascular disease 5 (3.2) | Results may not be applicable for reference as median age in our subject 29.87 ± 5.097 with comorbidity chronic respiratory disease 1 (6.67) and obesity 1 (6.67) |
- Citation: Karuniawati A, Syam AF, Achmadsyah A, Ibrahim F, Rosa Y, Sudarmono P, Fadilah F, Rasmin M. Case series in Indonesia: B.1.617.2 (delta) variant of SARS-CoV-2 infection after a second dose of vaccine. World J Clin Cases 2022; 10(36): 13216-13226
- URL: https://www.wjgnet.com/2307-8960/full/v10/i36/13216.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i36.13216